Letter | Published:

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

Nature volume 477, pages 107110 (01 September 2011) | Download Citation

Abstract

Parkinson’s disease is the second most common neurodegenerative disorder1,2. Growing evidence indicates a causative role of misfolded forms of the protein α-synuclein in the pathogenesis of Parkinson’s disease3,4. Intraneuronal aggregates of α-synuclein occur in Lewy bodies and Lewy neurites5, the cytopathological hallmarks of Parkinson’s disease and related disorders called synucleinopathies4. α-Synuclein has long been defined as a ‘natively unfolded’ monomer of about 14 kDa (ref. 6) that is believed to acquire α-helical secondary structure only upon binding to lipid vesicles7. This concept derives from the widespread use of recombinant bacterial expression protocols for in vitro studies, and of overexpression, sample heating and/or denaturing gels for cell culture and tissue studies. In contrast, we report that endogenous α-synuclein isolated and analysed under non-denaturing conditions from neuronal and non-neuronal cell lines, brain tissue and living human cells occurs in large part as a folded tetramer of about 58 kDa. Several methods, including analytical ultracentrifugation, scanning transmission electron microscopy and in vitro cell crosslinking confirmed the occurrence of the tetramer. Native, cell-derived α-synuclein showed α-helical structure without lipid addition and had much greater lipid-binding capacity than the recombinant α-synuclein studied heretofore. Whereas recombinantly expressed monomers readily aggregated into amyloid-like fibrils in vitro, native human tetramers underwent little or no amyloid-like aggregation. On the basis of these findings, we propose that destabilization of the helically folded tetramer precedes α-synuclein misfolding and aggregation in Parkinson’s disease and other human synucleinopathies, and that small molecules that stabilize the physiological tetramer could reduce α-synuclein pathogenicity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Missing pieces in the Parkinson’s disease puzzle. Nature Med. 16, 653–661 (2010)

  2. 2.

    , & What causes cell death in Parkinson’s disease? Ann. Neurol. 64, S3–S15 (2008)

  3. 3.

    , & The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 27, 336–349 (2008)

  4. 4.

    et al. Brain α-synuclein accumulation in multiple system atrophy, Parkinson’s disease and progressive supranuclear palsy: a comparative investigation. Brain 133, 172–188 (2010)

  5. 5.

    et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997)

  6. 6.

    , , , & NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35, 13709–13715 (1996)

  7. 7.

    , , & Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443–9449 (1998)

  8. 8.

    et al. Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions. Brain Res. 853, 5–14 (2000)

  9. 9.

    et al. GATA transcription factors directly regulate the Parkinson’s disease-linked gene α-synuclein. Proc. Natl Acad. Sci. USA 105, 10907–10912 (2008)

  10. 10.

    & Advantages and limitations of clear-native PAGE. Proteomics 5, 4338–4346 (2005)

  11. 11.

    et al. Cryoelectron microscopy structure of purified •-secretase at 12 Å resolution. J. Mol. Biol. 385, 642–652 (2009)

  12. 12.

    , , & Mass mapping of large globin complexes by scanning transmission electron microscopy. Methods Enzymol. 436, 487–501 (2008)

  13. 13.

    Mechanistic aspects of Parkinson’s disease: α-synuclein and the biomembrane. Cell Biochem. Biophys. 47, 285–299 (2007)

  14. 14.

    , & Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. Biochemistry 11, 4120–4131 (1972)

  15. 15.

    et al. α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl Acad. Sci. USA 98, 9110–9115 (2001)

  16. 16.

    , & Microdetermination of phosphorus. Anal. Chem. 28, 1756–1758 (1956)

  17. 17.

    , , , & Aggregates assembled from overexpression of wild-type α-synuclein are not toxic to human neuronal cells. J. Neuropathol. Exp. Neurol. 67, 1084–1096 (2008)

  18. 18.

    , , & Membrane association and protein conformation of α-synuclein in intact neurons. Effect of Parkinson’s disease-linked mutations. J. Biol. Chem. 275, 8812–8816 (2000)

  19. 19.

    et al. Formation of a high affinity lipid-binding intermediate during the early aggregation phase of α-synuclein. Biochemistry 47, 1425–1434 (2008)

  20. 20.

    et al. Distinct region-specific α-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J. Neurosci. 30, 3409–3418 (2010)

  21. 21.

    , , , & Detection of novel intracellular α-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 20, 2050–2057 (2006)

  22. 22.

    , & The tetrameric protein transthyretin dissociates to a non-native monomer in solution. J. Biol. Chem. 274, 32943–32949 (1999)

  23. 23.

    , , , & Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr. Opin. Struct. Biol. 20, 54–62 (2010)

  24. 24.

    & A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443, 774–779 (2006)

Download references

Acknowledgements

Mass measurements were carried out at the Brookhaven National Laboratory STEM facility, a user facility supported by the US Department of Energy. We are grateful to D. Walker and J. Anderson (Elan Pharmaceuticals) for conducting mass spectrometry of our purified α-synuclein samples and for comments. We thank X. Simon and I. Perovic (Brandeis University) for their assistance with the AUC and phosphate analyses. Supported by NIH grants NS051318 and NS038375 (D.J.S.). We thank our colleagues at the Center for Neurologic Diseases for many discussions.

Author information

Affiliations

  1. Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA

    • Tim Bartels
    • , Joanna G. Choi
    •  & Dennis J. Selkoe

Authors

  1. Search for Tim Bartels in:

  2. Search for Joanna G. Choi in:

  3. Search for Dennis J. Selkoe in:

Contributions

All experiments were planned by T.B. and D.J.S. and conducted by T.B. and J.G.C. The manuscript was prepared by T.B. and D.J.S.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Dennis J. Selkoe.

Supplementary information

PDF files

  1. 1.

    Supplementary Figures

    The file contains Supplementary Figures 1-11 with legends.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature10324

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.